'Brussels EU'

Homepage
About Us!
Educate!
Inform!
Newsletter
Contact Us!
Links
Sitemap

The Health Organization Founded by Dr. Rath is Unique in the World: All the Profits it Makes Go to a Non-profit Foundation. » Read More
Recipients of the “Relay of Life” from the Auschwitz Survivors. » Read More






About Us
Goals
Background
Dr. Rath
Dr. Niedzwiecki

News






Video








Science








Wiki-Rath








Library









Features







Your Country
















Brussels EU calls for curbs on citizen petitions

Back to article.



Back to article.







Page Tools:
Print This Page!
Inform A Friend!
Bookmark This Page!
Contact



What's New:
Dismantling the ‘Brussels EU’ – a precondition for global natural health freedom
Brussels EU continues attempts to curtail spread of lifesaving natural health information
How to use diagnostic technologies wisely and for the benefit of your health
Radio interview – Jon Rappoport Show
President Obama, Wake Up America!
Wake Up, America! Prevent Dicatorship And War!
What the 'Brussels EU' isn't telling you about the Lisbon Treaty
The Oil Cartel's Goal: Toppling the Obama Government
Brussels EU calls for curbs on citizen petitions
One Trillion Dollar Bailout Can No Longer Conceal the Nazi Roots of the 'Brussels EU'

© 2011 by Dr. Rath Health Foundation
About Us!
Contact Us!
Print This Page!
Inform A Friend!
Bookmark This Page!

Marijuana A Chronicle

http://www.youtube.com/watch?v=nbzu6bvVMG8&feature=player_detailpage

Russia Plans to open stores for medicinal cannabis in accordance with the law.

-------------------------------------------------------------
IACM-Bulletin of 24 April 2011
-------------------------------------------------------------

* Russia: Plans to open stores for medicinal cannabis in accordance
with the law
* Rwanda: Plans by the government to allow the medical use of
cannabis
* USA: The governor of Montana vetoed a bill that would have repealed
the medical cannabis law
* Canada: Cannabis law unconstitutional, an Ontario court ruled

1.

Russia: Plans to open stores for medicinal cannabis in accordance
with the law

The first store to sell cannabis for medicinal purposes will be
opened in Nizhny Novgorod. Persons under 18 years of age and pregnant
women will not be allowed to purchase the products. The opening is
planned for June 2011. Currently, the store chain management is
holding negotiations with suppliers. It is intended to open a network
of similar stores later in Moscow, Irkutsk and Samara.

As of December 2010, it is allowed by law to sell cannabis to the
severely ill in Russia. The State Duma approved a project to
distribute these psychotropic substances for medical purposes.
Cannabis is also known as an analgesic, antiepileptic, antispastic,
antiemetic and appetite improving medicine.

(Source: http://www.newsbcm.com of 1 April 2011)

2.

Rwanda: Plans by the government to allow the medical use of cannabis

In June last year, Rwanda took the initial steps in allowing cannabis
strictly for medical purposes, the first country in Africa to do so.
The proposed law provides that cannabis will only be administered in
health institutions to relieve pain and other severe diseases. The
Minister of Health, Dr Richard Sezibera, while presenting the draft
law to Parliament, said that the objective of the Bill was to
contribute to the protection of the population while "ensuring that
drugs and psychotropic substances are exclusively available for
scientific and medical purposes".

If the Bill passes into law, Rwanda will join the ranks of countries
such as The Netherlands, Israel and Canada, where, with a doctor's
prescription, patients are allowed to possess a small amount of the
drug to alleviate chronic debilitating symptoms such as neuropathic
pain and side effects of chemotherapy.

More at:
http://www.theeastafrican.co.ke/news/Ill+and+need+marijuana+Head+south
+to+Rwanda/-/2558/1145978/-/5alxgv/-/index.html

(Source: East African (Kenya) of 18 April 2011)

3.

USA: The governor of Montana vetoed a bill that would have repealed
the medical cannabis law

On 13 April Governor Brian Schweitzer vetoed a bill that would have
repealed Montana's voter-approved medical cannabis law, saying it
would have gone against the will of the people. Of the 15 states and
the District of Columbia that have medical cannabis laws, almost all
have struggled with how to adequately regulate a drug that the
federal government deems dangerous and addictive but said it would
not prosecute as long as users follow state law.

But the Montana Legislature took the unusual step of passing a bill
to completely overturn the 2004 law that was approved by Montana
voters. Republican leaders in the state Senate and House of
Representatives say the drug cannot be regulated safely because the
drug attracts criminal gangs and addicts the state's youth. Governor
Schweitzer said he agreed the medical cannabis law was written
broadly with unanticipated results, but that had to be balanced with
the medical needs of Montanans. "I believe the proper resolution of
this unanticipated outcome is not outright repeal, but amendment to
serve the original intent," he said.

More at:
-
http://hosted.ap.org/dynamic/stories/U/US_MEDICAL_MARIJUANA_MONTANA?SI
TE=FLTAM&SECTION=HOME&TEMPLATE=news_generic.htm
- http://www.reuters.com/article/2011/04/13/us-marijuana-montana-
idUSTRE73C6WQ20110413

(Sources: Associated Press of 13 April 2011, Reuters of 13 April
2011)

4.

Canada: Cannabis law unconstitutional, an Ontario court ruled

An Ontario court has struck down Canada's laws against possessing and
growing cannabis as part of a ruling that found the country's
medicinal cannabis program is failing to provide access to the drug
for those who need it. However, the government will appeal the ruling
before a higher court.

The Ontario ruling stemmed from the constitutional challenge of
Matthew Mernagh, a man who relies on medical cannabis to ease pain
brought on by fibromyalgia and scoliosis. Health Canada's medical
cannabis program regulates and approves growing and regulates how
much patients can buy and how much they're legally allowed to use for
their treatment. More than 9,800 Canadians are legally permitted to
possess medicinal cannabis, according to Health Canada. Nearly 5,600
people hold a personal grower's licence and 1,837 people hold a
licence to grow for one other person. However, Justice Donald Taliano
wrote in his decision on 11 April that Mernagh has been unable to get
a doctor to sign off on a medical cannabis licence. Other patients
run into the same problem, the judge noted, and that forces some
seriously ill people to obtain cannabis illegally.

More at:
http://stage.www.winnipegfreepress.com/breakingnews/marijuana-law-
unconstitutional-ontario-court.html?device=mobile

(Sources: Reuters of 13 April 2011, Winnipeg Free Press of 14 April
2011)

5.

News in brief

***Economy: GW Pharmaceuticals
On 11 April the British company GW Pharmaceuticals announced that it
has entered into an exclusive licence agreement for Novartis Pharma
to commercialise the cannabis extract Sativex in Australia and New
Zealand, Asia (excluding Japan, China and Hong Kong), Middle East
(excluding Israel/Palestine) and Africa. Under the terms of the
agreement, Novartis will have exclusive commercialisation rights to
Sativex and will also be responsible for regulatory filings.
(Sources: Press release by GW Pharmaceuticals of 11 April 2011,
Reuters of 11 April 2011)

***Czech Republic: Sativex
The cannabis extract Sativex has been approved in the Czech Republic
as a treatment for spasticity due to multiple sclerosis. This
approval is following the approval in the UK and Spain. Other
European countries are expected to follow in the coming months.
(Source: Press release by GW Pharmaceuticals of 15 April 2011)

***Science: Workshop on medical use
On 8 July 2011 during the ICRS Meeting the CCIC (Canadian Consortium
for the Investigation of Cannabinoids) organizes a symposium on
cannabinoids in medical practise. The speakers are Cecilia Hillard,
Linda Parker, Donald Abrams, Sachin Patel, Diego Centonze, William
Notcutt, and Mark Ware. More information at: www.ccic.net/symposium.
(Source: Personal Communication)

***Jamaica: Recommendations for legalization
The government will review recommendations to decriminalize
possession of small amounts of cannabis for personal and religious
use. They will evaluate a 2001 report by the National Commission for
Ganja - as cannabis is known locally. The commission appointed by the
government argued that the drug was "culturally entrenched" in
Jamaica and that moderate use had no negative health effects on most
users. (Source: Associated Press of 12 April 2011)

Cannabis and Pain Management

Wellness
With Every Breath We Take
Marijuana and Pain Management
By: Bill McCarberg, M.D.
Millions of people in the United States suffer from chronic pain, and much of that suffering cannot be relieved adequately by existing treatments. Patients are in desperate need of new pain management approaches. Cannabinoid medicines appear very promising, although the subject often is obscured by controversy, prejudice, and confusion in part because cannabinoids have some relation to the cannabis plant – also known by the slang term marijuana.

What scientific reasons do doctors have to think that cannabinoids actually work? Do they provide genuine symptom improvement, or do patients become intoxicated and merely think that their symptoms are reduced?

Basic research conducted over the past 20 years provides us with many answers. In the early 1990s, researchers identified the cannabinoid receptor system. This system is found in some of the most primitive animal forms on earth – it is also the most widespread receptor system in the human body.

The cannabinoid receptor system has two types of receptors:

CB1 receptors are found primarily in the brain, spinal cord, and periphery.
CB2 receptors are on the immune tissues.
Specific molecules (called endocannabinoids) are produced by the body that interact with these CB1 and CB2 receptors, much like endorphins interact with the body's opioid receptor system. These findings initiated a new era of scientific interest and research in cannabinoids.

Numerous studies have now established that cannabinoids help lessen pain and affect a wide range of symptoms and bodily functions. Such research has also demonstrated that cannabinoids may work together with opioids to enhance their effectiveness and reduce tolerance.

This body of research has allowed cannabinoids to be informally classified into three types:

endocannabinoids (produced by the body)
phytocannabinoids (produced by the cannabis plant)
synthetic cannabinoids (produced in the laboratory)
Each type is being studied aggressively, but because endocannabinoids are quickly metabolized and probably cannot be patented, they have not yet been researched in humans.

What progress is being made toward developing cannabinoids as prescription pain relievers? Some cannabinoids are unstable and many are insoluble in water, which makes them difficult to research and turn into modern medicines. Patients react very differently to cannabinoids. Data from recent clinical trials are encouraging, but somewhat mixed. Looking closely at the results suggests that composition and delivery route (i.e., how a medicine is administered) are extremely important to the viability of cannabinoid medicines.

The Delivery Route

When taken orally, cannabinoids are not very well absorbed and often have unpredictable effects. Patients often become sedated or have intoxication-like symptoms when tetrahydrocannabinol (THC – the primary psychoactive cannabinoid in cannabis) is metabolized by the liver. A small number of studies with Marinol (synthetic THC in sesame oil in a gelatin capsule) and Cesamet (synthetic THC analogue) have shown some effectiveness in pain relief, but optimal doses that relieve pain often cannot be achieved because of unpleasant psychologic side effects.

Inhaling cannabinoids, especially THC, also may cause problems for many patients. Blood levels rise suddenly and then drop off sharply. This rapid on-off effect may produce significant intoxication, particularly in patients who are new to cannabinoids. This may pose the risk of abuse potential. Smoking cannabis produces this effect, which is the very reason that recreational users prefer the inhaled route. Patients, however, generally wish to avoid psychologic effects, and it is unclear how difficult it might be to find a dosing pattern that enables them to have pain control without side effects.

A new product, called Sativex, was approved by Health Canada in June 2005 for marketing as an adjunctive medicine for central neuropathic pain in multiple sclerosis. Adjunctive therapy means taking two or more medications to help control pain.

Sativex has a different delivery system – an oromucosal/sublingual spray absorbed by the lining of the mouth – that, according to the manufacturer, generally allows patients to gradually work up to a stable dose at which they obtain therapeutic pain relief without unwanted psychologic effects.

In the United States, Sativex is being studied in large randomized trials in cancer pain that has not been adequately relieved by opioids. Three early and six pivotal controlled studies in the United Kingdom demonstrated positive results treating chronic pain of various origins including neurologic pain, various symptoms of multiple sclerosis, rheumatoid arthritis, and cancer pain. Initial results show improvement in pain for more than one year despite lack of effectiveness of the opioids. Common adverse effects of Savitex have included complaints of bad taste, stinging, dry mouth, dizziness, nausea or fatigue.

Additional research also may uncover other ways of avoiding the problems associated with oral or inhaled delivery. Ajulemic acid, a synthetic cannabinoid, binds to both the CB1 and CB2 receptors, and has shown benefit in a small neuropathic pain trial. It may have reduced psychologic effects and is being studied for the treatment of interstitial cystitis.

The Interplay of Cannabinoids

The use of herbal cannabis – usually smoked – has received considerable media attention since California and Arizona passed "medical marijuana" initiatives in 1996. Despite numerous anecdotal reports of effectiveness, very few controlled studies have been published in the pain area. Little is known about the number of patients who actually experience some degree of benefit or side effects.

Furthermore, herbal cannabis is neither standardized nor monitored for quality. The cannabinoid content can vary a great deal, and cannabis sold at dispensaries may be contaminated with pesticides or mold. Dosing is uncertain, depending on the preparation or method of use. So-called "vaporizers" do not eliminate all the contaminants. Without clinical trial data and an assurance of product quality, physicians lack the information necessary to assist patients in making informed therapeutic decisions. Both the FDA and Institute of Medicine have stated that there is no future for herbal cannabis as a prescription medicine.

Nevertheless, there may be some truth to the idea that there is pain relief potential in phytocannabinoids (plant-based cannabinoids) and that such potential may be affected by the interaction of THC with other botanical components, particularly with other cannabinoids. Modern strains of cannabis have been bred to maximize the THC at the expense of all other cannabinoids, most of which do not have psychologic effects. Some of those cannabinoids, such as cannabidiol (CBD), have been demonstrated to have important therapeutic value, particularly on pain and inflammation.

Concluding Thoughts

The possibilities for cannabinoid medicines are very promising, and much exciting research is proceeding at a rapid pace. As new FDA-approved cannabinoid products become available, physicians and patients will have a solid scientific foundation from which to assess their appropriateness. Hopefully, robust scientific data will soon allow cannabinoids to take their place – along with opiates and other pain relievers – in the modern medical supply for treating chronic pain.

Bill H. McCarberg, MD, is founder of the Chronic Pain Management Program for Kaiser Permanente, San Diego, and assistant clinical professor in the Department of Family Practice at the University of California, San Diego, School of Medicine. He has served on the board of directors of the American Pain Society and currently is co-president of the Western Pain Society and a National Pain Foundation Advisor.
Home About Us Contact Supporters Privacy Terms of Use Legal

Effects of Cannabis & Cancer

Effects of Cannabis & Cancer



Cannabis has been found to help cancer patients with pain and nausea, and recent research indicates it has tumor-reducing and anti-carcinogenic properties as well. It has proven highly effective at controlling the nausea associated with chemotherapy, and its appetite-stimulation properties help combat wasting. Cannabis can also help control the pain associated with some cancers, as well as that resulting from radiation and chemotherapy treatment.

Cannabis and chemotherapy side effects

One of the most widely studied therapeutic applications for cannabis and the pharmaceutical drugs derived from cannabinoids is in the treatment of nausea and vomiting associated with cancer chemotherapy. Numerous clinical studies have reported that the use of cannabis reduces nausea and vomiting and stimulates appetite, thereby reducing the severity of cachexia, or wasting syndrome, in patients receiving chemotherapy treatment.

The 1999 Institutes of Medicine report concluded: "In patients already experiencing severe nausea or vomiting, pills are generally ineffective, because of the difficulty in swallowing or keeping a pill down, and slow onset of the drug effect. Thus an inhalation (but, preferably not smoking) cannabinoid drug delivery system would be advantageous for treating chemotherapy-induced nausea."[58]

A 1997 inquiry by the British Medical Association found cannabis more effective than Marinol, and a 1998 review by the House of Lords Science & Technology Select Committee concluded that "cannabinoids are undoubtedly effective as anti-emetic agents in vomiting induced by anti-cancer drugs. Some users of both find cannabis itself more effective."[59, 60]

In the last three years, there have been major advances in both cannabinoid pharmacology and in understanding of the cancer disease process. In particular, research has demonstrated the presence of numerous cannabinoid receptors in the nucleus of the solitary tract, a brain center important in control of vomiting.

Although other recently developed anti-emetics are as effective or more effective than oral THC, nabilone or smoked cannabis, for certain individuals unresponsive to conventional anti-emetic drugs, the use of smoked cannabis can provide relief more effectively than oral preparations which may be difficult to swallow or be vomited before taking effect, as the IOM report notes.

The psychoactive euphoriant effects of THC or inhaled cannabis may also provide an improvement in mood. By contrast, several conventional medications commonly prescribed for cancer patients, e.g. phenothiazines such as haloperidol (known as "major tranquillizers"), may produce unwanted side effects such as excessive sedation, flattening of mood, and/or distressing physical "extrapyramidal" symptoms such as uncontrolled or compulsive movements.

While clinical research on using cannabis medicinally has been severely limited by federal prohibition, the accumulated data speaks strongly in favor of considering it as an option for most cancer patients, and many oncologists do. Survey data from a Harvard Medical School study in 1990, before any states had approved medical use, shows that 44% of oncologists were then recommending cannabis to at least some of their patients. Nearly half said they would do so if the laws were changed. According the American Cancer Society's 2003 data, more than 1,300,000 Americans are diagnosed with cancer each year.[61] At least 300,000 of them will undergo chemotherapy, meaning as many as 132,000 patients annually may have cannabis recommended to them to help fight the side effects of conventional treatments.

As the Institutes of Medicine report concluded, "nausea, appetite loss, pain and anxiety … all can be mitigated by marijuana."

Research on cannabis and chemotherapy

Cannabis is used to combat pain caused by various cancers and nausea induced by chemotherapy agents. Over 30 human clinical trials have examined the effects of cannabis or synthetic cannabinoids on nausea, not including several U.S. state trials that took place between 1978 and 1986.[62] In reviewing this literature, Hall et al. concluded that ". . . THC [delta-9-tetrahydrocannabinol] is superior to placebo, and equivalent in effectiveness to other widely-used anti-emetic drugs, in its capacity to reduce the nausea and vomiting caused by some chemotherapy regimens in some cancer patients."[63] A 2003 study found "Cannabinoids—the active components of Cannabis sativa and their derivatives—exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite. In addition, these compounds have been shown to inhibit the growth of tumor cells in culture and animal models by modulating key cell-signaling pathways. Cannabinoids are usually well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies."[64] Authors of the Institute of Medicine report, "Marijuana and Medicine: Assessing the Science Base," found that there are many cancer patients for whom cannabis should be a valid medical option.[65]

A random-sample anonymous survey conducted in the spring of 1990 measured the attitudes and experiences of oncologists concerning the antiemetic use of cannabis in cancer chemotherapy patients. Of the respondents expressing an opinion, a majority (54%) thought cannabis should be available by prescription.[66]

Cancer-fighting properties of cannabis

Recent scientific advances in the study of cannabinoid receptors and endocannabinoids have produced exciting new leads in the search for anti-cancer treatments. More than twenty major studies published between 2001 and 2006 have shown that the chemicals in cannabis known as cannabinoids have a significant effect fighting cancer cells. We now know cannabinoids arrest many kinds of cancer growths (brain, breast, leukemic, melanoma, phaeochromocytoma, etc.) through promotion of apoptosis (programmed cell death) that is lost in tumors, and by arresting angiogenesis (increased blood vessel production).

There is growing evidence of direct anti-tumor activity of cannabinoids, specifically CB1 and CB2 agonists, in a range of cancer types including brain (gliomas), skin, pituitary, prostate and bowel. The anti-tumor activity has led in laboratory animals and in-vitro human tissues to regression of tumors, reductions in vascularisation (blood supply) and metastases (secondary tumors), as well as the direct destruction of cancer cells (apoptosis). Indeed, research on the complex interactions of endogenous cannabinoids and receptors is leading to greater scientific understanding of the basic mechanisms by which cancers develop.

The findings of these studies are borne out by the anecdotal reports of such patients as Steve Kubby, whose cannabis use is credited with keeping rare, terminal cancers in a state of remission for decades beyond conventional expectations.

Research on Tumor Reduction

Although cannabis smoke has been shown to have precancerous-causing effects in animal tissue, epidemiological studies have failed to link cannabis smoking with cancer.[67-68] If smoke inhalation is a concern, cannabis can be used with a vaporizer, orally in baked goods, and topically as a tincture or a suppository.

Cannabinoids, the active components of cannabis, have been shown to exhibit anti-tumor properties. Multiple studies published between 2001 and 2003 found that cannabinoids inhibit tumor growth in laboratory animals.[69-73] In another study, injections of synthetic THC eradicated malignant brain tumors in one-third of treated rats, and prolonged life in another third by as much as six weeks.[74] Other journals have also reported on cannabinoids' antitumoral potential.[75-81] Italian research teams reported in 1998 and 2001 that the endocannabinoidanandamide, which binds to the same brain receptors as cannabis, "potently and selectively inhibits the proliferation of human breast cancer cells in vitro" by interfering with their DNA production cycle.[82-84] Cannabis has been shown in recent studies to inhibit the growth of thyroid, prostate and colorectal cancer cells.[85-87] THC has been found to cause the death of glioma cells.[88-89] And research on pituitary cancers shows cannabinoids are key to regulating human pituitary hormone secretion.[90-93]

In 2004 an Italian research team demonstrated that the administration of the non-psychoactive cannabinoid cannabidiol (CBD) to nude mice significantly inhibited the growth of subcutaneously implanted U87 human glioma cells. The authors of the study concluded that "… CBD was able to produce a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent (an agent that inhibits the growth of malignant cells.)"[94]

More recently, investigators at the California Pacific Medical Center Research Institute reported that the administration of THC on human glioblastomamultiforme cell lines decreased the proliferation of malignant cells and induced apoptosis (programmed cell death) more rapidly than did the administration of an alternative synthetic cannabis receptor agonist.[95]

Communities and Local Government

* Jump to the main content
* Jump to the quick search

Related sites

* Home
* Contact us
* What's new
* Help
* Sitemap

Communities and Local Government

A selection of images representing communities.

* Direct contact 0303 444 0000
* contactus@communities.gov.uk

Search the entire site or publications
Search
Search
All content Publications

* Advanced search

Communities and neighbourhoods

* About communities and neighbourhoods
* Digital Inclusion
* Community empowerment
* Race, cohesion and faith
* Prevent
* Neighbourhood renewal
* Place matters
* Third sector, community and voluntary groups
* Help using our website

News

* Latest news
* Speeches, statements and articles
* News feeds and alerts

Publications

* All publications
* Circulars and official letters
* Consultations
* Corporate reports
* Good practice and guidance
* Impact assessments
* Legislation and policy
* Manuals, leaflets and booklets
* Newsletters
* Reports and summaries
* Research
* Statistics
* Strategies and action plans

* Communities and neighbourhoods
* Publications
* All publications
* Our Nation's Civic Health - Annex B

Communities and neighbourhoods
Content under review

Following the change of government we are reviewing all content on this website.
Our Nations Civic Health - Annex B
Our Nation's Civic Health - Annex B
Published 31 March 2010
Type(s) Research, Reports and summaries
Site Communities and neighbourhoods
Product code 09CA06290
ISBN 9781409823605
Price Free
Summary

This is Annex B to the main report, which brings together for the first time, key measures of civic health in order to offer a unique insight into the strengths of modern democracy in England and the connections people have to their communities. It reveals key trends over time and, where possible, shows how civic health varies across the country. It is hoped that presenting this information in this way will help readers understand the complex factors that contribute to how people feel about and engage with their community.

The findings and recommendations in this report are those of the consultant authors and do not necessarily represent the views or proposed policies of Communities and Local Government.
Order

* This publication is only available online - see below to download.

Download

* Our Nation's Civic Health - Annex B
PDF, 3897 kb , 92 pages

Do you need help viewing file formats?
Alternative formats
If you require this publication in an alternative format (eg Braille or audio) please email alternativeformats@communities.gsi.gov.uk quoting the title and product code/ISBN of the publication, and your address and telephone number.
Related publications

*
Our Nation's Civic Health - Main Report
o Published: 31 March 2010
o Site: Communities and neighbourhoods
*
Our Nation's Civic Health - Summary Report
o Published: 31 March 2010
o Site: Communities and neighbourhoods
*
2007-08 Citizenship Survey: Empowered Communities Topic Report
o Published: 29 September 2009
o Site: Corporate

You may also be interested in …
On this site

* Measuring empowerment
* Community empowerment

Communities on Twitter

Keep up to date with the Department by following us on Twitter.
Have your say

* Discussion forums
* Newsletters
* Feedback

My favourites

You currently have no favourites saved.

POPULAR LINKS

* Copyright
* Terms and conditions
* Privacy policy
* Accessibility
* Freedom of information

Directgov
info4local

Oprah Turns Her Back - Legalities of Hemp Cure

This is not a Drug issue, not even a legal issue, it is a people issue! A man named Rick Simpson approaches the Canadian government after discovering a product that has cured many different illness's including cancers.
One would think, that a man who is sane and respectable, and approaches the authorities of his Country with a cure for cancer, well one would believe, or like to believe, that there would be some type of interest. Then scientist's would find out about this possible cure for cancer.

Basically, Rick was naive to some extent, he was honest and had already told the authorities what he was doing i.e. making the hemp oil from his own plants. But nothing happened and he carried and made his medication which actually cures most cancers.

When Rick went to trial in Canada he had 10 people who no longer had cancer and were there to give testimony & six of these people were accompanied by there doctors who were also to give testimonials, however the Judge dis-allowed them from giving evidence.

Rick was not sent to prison. In November 2010, he was invited to Amsterdam to accept the award for 'freedom fighter' of the year. While in Netherlands the police again raided his home, taking plastic bowls and other things that they did not take at the last bust. They also took his security camera's but luckily his eldest son arrived at the house and filmed the raid from outside the house.
Rick Simpson is still in exile in Europe.

Health » health, , , looks more like money-making for its own sake to me.
irrah.


Chatter ShmatterPfizer shifts focus to cancer and biotech drugsThe Associated Press - 56 minutes agoTRENTON, NJ (AP) - Pfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as cancer and Alzheimer's disease.

Pfizer Advances Pipeline Drugs But Narrows Focus CNNMoney.comPfizer to focus on more profitable diseases

International Herald TribuneTheStreet.com - WTNH - Reuters - MarketWatchall 171 news articles »